SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-20-101906
Filing Date
2020-09-02
Accepted
2020-09-02 17:15:27
Documents
1
Period of Report
2020-08-31

Document Format Files

Seq Description Document Type Size
1 4 a4.html 4  
1 4 a4.xml 4 3046
  Complete submission text file 0001104659-20-101906.txt   4495
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Issuer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address
Schranz Jennifer (Reporting) CIK: 0001735382 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37558 | Film No.: 201157589